CDTHealthcare · Biotechnology

CDT Stock Forecast: CDT Equity, Inc. Price Predictions for 2026-2027

Last close, 12 Oct 2026

$0.66

−8.08% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 15 of 100 as at 12 Oct 2026 — in the weakest quartile.

Market cap

$26,757.00

Ticker Nerd rank

15 / 100

Median analyst target

—

Analysts covering

—

Revenue$0.0

Operating income−$3.0M

Net income−$4.6M

Free cash flow−$544K

Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown

Total return, dividends reinvested

−28.1%

−89.4%

YTD

−100.0%

From 52W high

−100.0%

From 52W low

0.0%

$26,125

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

CDT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores CDT Equity, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Oct 2026

15 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

100

Accruals

Growth

Volatility

Quality

Issuance

Revisions

Value

Momentum

Size (100): Smaller than most of the companies we track.

Momentum (2): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CDT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CDT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CDT appears on the weeks it earns a place.

Performance

CDT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 12 Oct 2026, CDT Equity, Inc. returned −100.0% against +20.4% for the S&P 500, dividends included.

CDT vs S&P 500, last 12 monthsTotal return, rebased to 100

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CDT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

CDT Equity, Inc. (CDT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: 0.0×
Price / sales: —
Price / book: 0.0×
EV / EBITDA: −0.0×

Growth & margins

Revenue growth (YoY): —
Earnings growth (YoY): —
Gross margin: —
Operating margin: 0.0%
Net margin: 0.0%

Returns & dividend

Return on equity: −69.7%
Return on assets: −23.4%
Dividend yield: 0.0%

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

CDT Equity, Inc. (CDT) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

CDT Equity, Inc. has a market value of $27K and an enterprise value of $456K.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$37.1M.
Free cash flow in the twelve months to 30 June 2026: −$13.5M.
Shares outstanding: 472,245.
Trailing P/E: 0.0×.
Forward dividend yield: 0.00%, paying out 0% of earnings.
CDT Equity, Inc. employs 4 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Oct 2026

Data provided by Twelve Data

Peers

CDT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology

Company	Market cap	TKN rank
CDTCDT Equity, Inc.	$26,757.00	15
BBLGBone Biologics Corp.	$1.3M	22
MLECMoolec Science SA	$1.3M	4
CRISCuris, Inc.	$1.3M	37
HELPHelus Pharma, Inc.	$1.5M	—
ARTLArtelo Biosciences, Inc.	$1.7M	17
LABTLakewood-Amedex Biotherapeutics, Inc.	$1.7M	21

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own CDT Equity, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CDT news & analysis

CDT Highlights Sarborg's Expanding Quantum Computing IP Portfolio and Application to Drug Discovery

GlobeNewsWire · 29 Sept 2026positive

CDT is highlighting Sarborg's expanding quantum computing intellectual property portfolio and its application to drug discovery. The announcement was made from locations in Naples, Florida, and Cambridge, United Kingdom, in September.

Why it matters — A CDT watcher would care because the growth of Sarborg's quantum computing IP and its drug-discovery application could broaden CDT's technology capabilities and market positioning.

CDT Equity Inc. Announces Reverse Stock Split

GlobeNewsWire · 25 Sept 2026neutral

CDT Equity Inc. announced that its board of directors approved a 1-for-25 reverse stock split of its common stock to ensure continued compliance with the Nasdaq bid-price rule. Stockholders had previously approved future reverse stock splits and granted the board authority to determine their timing and exact ratios.

Why it matters — The reverse stock split is intended to keep CDT compliant with Nasdaq listing requirements, which is material to shareholders since it can affect the company's stock price and continued listing status.

CDT Partners with QIMA Life Sciences to Evaluate Novel Tapinarof Combinations in Psoriasis and Vitiligo

GlobeNewsWire · 18 Sept 2026positive

CDT has entered a partnership with QIMA Life Sciences to evaluate novel tapinarof combinations for the treatment of psoriasis and vitiligo. The collaboration will assess combination approaches involving CDT's tapinarof product.

Why it matters — This partnership signals CDT's continued investment in expanding its tapinarof pipeline into new combination therapies for dermatological conditions.

CDT Highlights Sarborg's Application of Signature Intelligence and Quantum Computing Models to Mental Health

GlobeNewsWire · 10 Sept 2026neutral

CDT highlighted Sarborg's application of its Signature Intelligence and quantum computing models to the field of mental health, as announced from Naples, Florida and Cambridge, United Kingdom. The announcement focuses on the technological application of these models in this domain.

Why it matters — A CDT watcher would care because it showcases how CDT's Signature Intelligence and quantum computing capabilities are being applied to a new and significant sector, potentially expanding the practical uses of its technology.

CDT Provides Capital Update and Confirms No Nasdaq Deficiencies

GlobeNewsWire · 2 Sept 2026positive

CDT Equity, Inc. issued a capital update confirming it has no Nasdaq deficiencies. The announcement was released from the company's Naples, Florida and Cambridge, United Kingdom offices.

Why it matters — CDT watchers would care because confirmation of no Nasdaq listing deficiencies signals the company remains compliant with exchange requirements.

FAQ

Frequently asked questions about CDT stock

How does Ticker Nerd's model rank CDT?

As at 12 Oct 2026, CDT Equity, Inc. ranks 15 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (100 of 100).

What is the CDT stock forecast for 2030?

No analyst covering CDT Equity, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CDT are extrapolating price history, which says nothing about the business.

How has CDT stock performed over the past year?

CDT Equity, Inc. returned -100.0% over the 12 months to 12 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does CDT Equity, Inc. do?

CDT Equity Inc. is a data-driven biopharmaceutical company focused on identifying, enhancing, and advancing therapeutic assets through scientific innovation and strategic partnerships.

What is the latest news on CDT?

The most recent item we track (GlobeNewsWire, 29 Sept 2026): "CDT Highlights Sarborg's Expanding Quantum Computing IP Portfolio and Application to Drug Discovery". CDT is highlighting Sarborg's expanding quantum computing intellectual property portfolio and its application to drug discovery. The announcement was made from locations in Naples, Florida, and Cambridge, United Kingdom, in September.

Company

About CDT Equity, Inc.

CDT Equity Inc. is a data-driven biopharmaceutical company focused on identifying, enhancing, and advancing therapeutic assets through scientific innovation and strategic partnerships. CDT Equity Inc. develops clinical-stage programs across autoimmune diseases, oncology, dermatology, idiopathic male infertility, rare diseases, and animal health. Its current portfolio includes compounds such as AZD1656, AZD5658, and AZD5904, supported by an approach that combines artificial intelligence, solid-form chemistry, and asset repositioning to improve development efficiency. The company emphasizes value creation through intellectual property, out-licensing, and partnerships rather than large-scale internal drug development. CDT Equity Inc. serves as a specialized participant in the healthcare sector, aiming to bring differentiated treatment candidates into clinical and commercial pathways.

CEO Mr. James Bligh · 4 employees · United States · https://www.cdtequity.com